Table 1.
Reference | Cell line | Differentiation protocol |
Myogenic markers detected in DMD- hiPSC myogenic cultures (protein) |
Myogenic differentiation |
DMD Phenotype in vitro |
Engraftment |
---|---|---|---|---|---|---|
Goudenege et al., 2012 | DMD patient hiPSC and healthy controls | MYOD1 overexpression (Adenovirus) | MYOD1, MHC, Spectrin, Lamin A/C | Similar to control | Larger myotubes compared to healthy controls | Performed in rag/mdx mice with/without cardiotoxin. Documented presence of hybrid myofibers |
Abujarour et al., 2014 | DMD patient hiPSCs and healthy controls | Doxycycline-dependent MYOD1 overexpression (Lentivirus) | MHC, MYOD1, MYOG, NCAM, CD44, CD29 | Similar to control | No | |
Shoji et al., 2015 | DMD patient hiPSCs and healthy controls treated or not with exon-skipping oligonucle otides | Tetracycline-dependent MYOD1 overexpression (PiggyBac vector) | CKM, MHC, Skeletal Muscle Actin | Similar to control | Excess of calcium flux (Fluo-8 dye) upon electrical stimulation | No |
Young et al., 2016 | DMD patient hiPSCs and CRISPR edited version rescued by deletion of exon 45-55 | Tamoxifen-dependent MYOD1 overexpression (Lentivirus) or Shelton et al. (2014) directed differentiation protocol | MHC, NCAM, Spectrin, Lamin A/C | Similar to control | β-dystroglycan downregulation and mislocalization | Performed in NOD-SCID-IL2rgnull (NSG)-mdx mice with cardiotoxin. Documented presence of engrafted myofibers by human Spectrin and Lamin A/C expression |
Choi et al., 2016 | DMD patient hiPSCs, healthy controls and correction with human artificial chromoso me expressing DMD | CHIR/DAPT treatment in N2 medium, replating and FACS sorting of NCAM+/HNK1− cells | Desmin, Lamin A/C, Laminin | Defective | Decreased fusion and myogenic marker expression. Absence of spontaneous contractions. Increased branching. Increased levels of BMP4 and TGFβ signaling. Increased expression of interleukins 6 and 8 and collagen 3 | Performed in NOD-Rag1nu11 IL2rgnu11 (NRG) mice and NSG-mdx mice after cardiotoxin. Comparable levels of human myofiber formation in both models |
Maffioletti et al., 2018 | DMD Patient hiPSC lines and healthy controls | Tamoxifen-dependent MYOD1 overexpression (Lentivirus) or directed differentiation (Caron et al., 2016) and 3D constructs | Laminin, Lamin A/C, MHC, Sarcomeric actin | Similar to control | Performed in NSG mice previously injured. Documented presence of engrafted myofibers by human Lamin A/C and embryonic MHC expression | |
Caputo et al., 2020 | DMD patient hiPSC lines and healthy controls | Doxycycline-dependent MYOD1 and BAF60C overexpression (PiggyBac vector) | MYOD1, Desmin, MHC | Similar to control | DMD hiPSC-derived myotubes exhibit constitutive activation of TGFβ-SMAD2/3 signaling. Electrically paced DMD hiPSC-derived myotubes exhibit greater and persistent increase in the expression of pro-fibrotic genes (TGFβ1, TGFβ2, IL6, and CTGF) | No |
Moretti et al., 2020 | DMD patient hiPSC line, CRISPR edited version rescued by deletion of exon 51 and healthy control | Commercial kit Amsbio; SKM-KITM | Not detected | Defective | No multinucleated myotubes | No |
Al Tanoury et al., 2020 | DMD patient hiPSC, CRISPR edited version rescued, CRISPR-engineered DMD mutants and isogenic healthy parental control | Directed differentiation (Chal et al., 2015, 2016) | MYOG, Desmin, Titin, α-actinin, NCAM, nNOS, DAG1 and delta-Sarcoglycan | Defective | Increased branching and fusion. Mislocalization of proteins of the Dystrophin-associated Glycoprotein Complex. Force contraction defects and Ca2+ hyper-excitability | No |